Skip to content
OpenCapital
Get started

Viatris VTRS Xalabrands — Net Sales

Other product segments

Brands
$2.33B+10.2%
Generics
$1.18B+4.5%
Lipitor
$462M+19.1%
Norvasc
$210M+21.9%
Lyrica ®
$120.6M+7.1%
EpiPen® Auto-Injectors
$101.1M+4.6%
Creon ®
$97.4M+18.2%
Viagra ®
$95M-3.6%
Zoloft ®
$72.6M+20.6%
Celebrex ®
$67.1M+5.8%
Yupelri ®
$62.5M+7.2%
Effexor ®
$62M+4.6%
Dymista ®
$37.3M-12.9%
Xanax ®
$34.8M+7.7%

Similar metrics at other companies

Acuity Brands logo
AYIABL — Net Sales
$905.2M-1.9%
Malibu Boats, Inc. logo
MBUUSaxdor — Net Sales
$23.14M—
Aaon logo
AAONBasX — Net Sales
$135.36M+104%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Incyte logo
INCYNet sales — Total revenues
$1.49B+40.5%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$20.8B+92.8%
Enterprise value$33.61B+34.5%
P/S1.4×+0.7×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's xalabrands — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's xalabrands — net sales?
Viatris (VTRS) reported xalabrands — net sales of $39.2M in Q1 2026.
How has Viatris's xalabrands — net sales changed year-over-year?
Viatris's xalabrands — net sales increased by 5.7% year-over-year, from $37.1M to $39.2M.
What is the long-term trend for Viatris's xalabrands — net sales?
Over 4 years (2021 to 2025), Viatris's xalabrands — net sales has grown at a -8.5% compound annual growth rate (CAGR), from $226M to $158.4M.
What does xalabrands — net sales mean?
This metric represents the total revenue generated from the sale of the Xalabrands product portfolio after accounting for returns, allowances, and discounts. It serves as a key indicator of the market demand and commercial performance for this specific brand segment within the company's broader pharmaceutical offerings. Monitoring these sales helps investors assess the lifecycle stage and competitive positioning of these legacy or specialized assets.